High impact
MA06.001g, Apheresis Therapy
Independence Blue Cross·Effective Jun 8, 2026
Independence Blue Cross Medicare Advantage has significantly restricted coverage for extracorporeal photopheresis (ECP) treatment of chronic lung allograft dysfunction. ECP is now covered ONLY for bronchiolitis obliterans syndrome (BOS) following lung transplant when refractory to standard immunosuppressive therapy AND enrolled in a Medicare-approved clinical study under Coverage with Evidence Development (CED). All other indications (restrictive allograft syndrome and non-refractory BOS) are no longer covered. CPT code 90997 (hemoperfusion) has been added as medically necessary.